Since its earliest use, the Magtrace® node marker has been subject to numerous regulatory approvals, clinical studies and peer-review papers.
Here you can read the clinical assessments in full and see how the Magtrace® node marker compares to alternative technologies.
The Magtrace® node marker is non-inferior to the standard technique of radioisotope and blue dye for axillary SLN detection in early-stage breast cancer.
A Meta-analysis that concludes the Magtrace® node marker is non-inferior to standard Tc99 with or without blue dye.
A Meta-analysis showing Magtrace® node marker non-inferiority versus ‘conventional techniques’ for SLNB in addition to reporting on a multicentre prospective trial
Meta-analysis showing SPIO is non-inferior to the standard technique with a significantly higher node retrieval rate
The Sentimag® probe is a safe SLN identification method and has a low risk of complications
78.3% of patients were able to avoid an unnecessary SLNB.
This study evaluates the feasibility of using MRI following the administration of the Magtrace® node marker for pre-operative localization of SLN’s and its potential for non-invasive identification of lymph node metastases
If you would like to read additional literature relating to the Magtrace® node marker and its safety, effectiveness and clinical results, please get in touch and we will be happy to assist you.